Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Other Operating Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Operating Expenses for 7 consecutive years, with -$126.2 million as the latest value for Q1 2025.

  • Quarterly Other Operating Expenses fell 19.55% to -$126.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$126.2 million through Dec 2025, down 154.18% year-over-year, with the annual reading at -$507.4 million for FY2023, 38.83% down from the prior year.
  • Other Operating Expenses for Q1 2025 was -$126.2 million at Beam Therapeutics, down from $338.5 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $338.5 million in Q4 2024, with the low at -$507.4 million in Q4 2023.
  • Average Other Operating Expenses over 5 years is -$127.9 million, with a median of -$115.9 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses crashed 38.83% in 2023, then surged 166.73% in 2024.
  • Over 5 years, Other Operating Expenses stood at -$1.2 million in 2021, then tumbled by 30688.63% to -$365.5 million in 2022, then crashed by 38.83% to -$507.4 million in 2023, then soared by 166.73% to $338.5 million in 2024, then plummeted by 137.28% to -$126.2 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$126.2 million, $338.5 million, and -$105.6 million for Q1 2025, Q4 2024, and Q1 2024 respectively.